MedTrace Logo

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

NCT03097068 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-10-24

Study results available
· View outcomes & findings →

Summary

The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.

Conditions

Interventions

DRUG

Lucentis

0.3mg Lucentis

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Michigan State University

    collaborator OTHER

  • Vitreo-Retinal Associates, Michigan

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-19
Primary Completion
2017-12-06
Completion
2018-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03097068 on ClinicalTrials.gov